Skip to main content
OpenTrials
Completed

NCT Number: NCT05294965

Beta 2 Adrenergic Stimulation vs Cold Exposure to Activate Human Brown Adipose Tissue

The purpose of the study is to asses brown adipose tissue activity in humans after intravenous administration of the selective beta-2-adrenergic agonist fenoterol as compared to the natural activator of brown adipose tissue, a mild cold stimulus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University Hospital Basel, Dept. of Endocrinology

Basel, Switzerland

About this study

The activation of brown adipose tissue in response to beta-2-adrenergic stimulation as compared to cold exposure will be studied in an open-label, cross-over trial in healthy volunteers with random sequence of the two study interventions a) and b):

  • A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose of fenoterol per subject will thus be 145µg.
  • During 120 minutes participants will be exposed to a mild cold stimulus water using cooling sleeves, covering the participant's waist, is gradually decrease body surface temperature to 10 degrees or to the lowest tolerable temperature without shivering.

Energy expenditure will be measured during both interventions by indirect calorimetry and brown adipose tissue activity will determined by 18F-FDG-PET/CT 30 min after injection of 75 MBq of 18F-FDG.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI 18,5-23 kg/m2 or 30-35 kg/m2

Exclusion criteria

  • History or signs of any medical or psychological condition
  • pregnancy or lactation
  • medications except prescription free analgesics and contraceptives
  • habitual alcohol or tobacco use
  • weight change >5% within prior 3 months
  • Resting heart rate >85 bpm
  • Systolic blood pressure >140 mmHg or diastolic blood pressure <50 mmHg
  • Presence of following ECG changes: ST-segment deviations, QTc >500ms, signs of pre-excitation
  • Hyper- or Hypothyroidism
  • inability to follow study procedures
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • hypersensitivity to cold
  • enrolment into study with ionizing radiation within prior 12 months.
  • Cold induced thermogenesis of less than 5% basal metabolic rate and normal weight or cold induced thermogenesis of more than 5% and overweight (determined during screening visit)

Treatment and study plan

Fenoterol

Drug

Intravenous infusion

Other names: beta2 adrenoreceptor agonist

Mild cold exposure

Other

Body surface cooling

Primary outcomes

  1. BAT SUVmean

    Time frame: 30 minutes after end of intervention

    18F-FDG uptake into the supra-clavicular brown adipose tissue as determined by 18F-FDG PET-CT after the respective study intervention

Secondary outcomes

  1. BAT SUVmax

    Time frame: 30 minutes after intervention

    maximum SUV in supraclavicular adipose tissue (according to BARCIST 1.0)

  2. BAT Volume

    Time frame: 30 minutes after intervention

    volume of supraclavicular adipose tissue (according to BARCIST 1.0)

  3. BAT glycolytic volume

    Time frame: 30 minutes after intervention

    volume of supraclavicular adipose tissue x SUVmean (according to BARCIST 1.0)

  4. Change in energy expenditure

    Time frame: First and last 30 minutes of intervention

    Quantitative change in EE above resting metabolic rate in response to the respective study intervention. Measured by indirect calorimetry.

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Acronym: ASCENT

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 24, 2022
Registry last updated
Sep 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.